Proficio Capital Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Proficio Capital Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-253	Closed	-$7K	–	134
2019 Q2	$7K	Hold	253	–	–	﹤0.01%	1060
2019 Q1	$7K	Buy	253 +203	+406%	+$4.74K	﹤0.01%	984
2018 Q4	$1K	Buy	+50	New	+$971	﹤0.01%	1075
2018 Q3	–	Sell	-16	Closed	–	–	1243
2018 Q2	$0	Sell	16 -257	-94%	-$4.58K	﹤0.01%	1274
2018 Q1	$6K	Buy	273 +63	+30%	+$1.74K	﹤0.01%	950
2017 Q4	$6K	Buy	210 +172	+453%	+$5.5K	﹤0.01%	923
2017 Q3	$1K	Hold	38	–	–	﹤0.01%	1136
2017 Q2	$1K	Hold	38	–	–	﹤0.01%	1135
2017 Q1	$1K	Buy	38 +16	+73%	+$565	﹤0.01%	1185
2016 Q4	$1K	Buy	+22	New	+$582	﹤0.01%	977

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Proficio Capital Partners's ACAD Position: Q3 2019 in Review

Proficio Capital Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 253 shares — an estimated $7K sold.

Proficio Capital Partners first reported a position in ACAD in Q4 2016 and held it in 10 quarters. The position peaked at $7K in Q2 2019. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Proficio Capital Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Proficio Capital Partners sold 253 Acadia Pharmaceuticals shares in Q3 2019, an estimated $7K.
Proficio Capital Partners first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 10 quarters.
Proficio Capital Partners's Acadia Pharmaceuticals position peaked at $7K in Q2 2019.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.